Biotechnology company BioMimetix JV LLC announced on Thursday the publication of results from a multicentre Phase I/II clinical trial evaluating BMX-001, a redox-active metalloporphyrin compound, in patients undergoing chemoradiation for locally advanced head and neck squamous cell carcinoma (HNSCC).
The single-arm Phase I/II study enrolled 29 patients with stage III–IV head and neck squamous cell carcinoma who received the investigational drug, BMX-001, in combination with chemoradiation therapy. It found that BMX-001 was safe and well tolerated and suggested substantial efficacy in mitigating treatment-related toxicities, including oral mucositis, xerostomia, and radiation dermatitis, in patients who received standard of care chemoradiation.
The results have been published in the International Journal of Radiation Oncology, Biology, Physics.
BMX-001 is a redox-active superoxide dismutase mimic that down-regulates oxidative stress pathways associated with radiation therapy, while stimulating repair pathways. These same impacts of BMX-001 inhibit tumour cell growth because of the unique metabolic pathways active in tumours. Preclinical studies show that BMX-001 protects normal tissues from radiation-induced injury while enhancing tumour responses to treatment.
Anixa Biosciences and Curia to finalise formulation of breast cancer vaccine for Phase 2 trial
Akagera Medicines receives Gates Foundation grant expansion to advance tuberculosis vaccine
Ten63 Therapeutics launches BEYOND-Alpha early adopter programme
Eloxx Pharmaceuticals publishes Phase 2a exaluren data in nonsense mutation Alport syndrome
Bristol Myers Squibb reports first Phase 3 data for KarXT in Alzheimer's-related psychosis
Pfizer signs licensing agreement with Starna Therapeutics worth up to USD2.63bn
Inhibrx updates clinical data for ozekibart (INBRX-109) in Ewing sarcoma
Dicot Pharma initiates phase 2b clinical study of erectile dysfunction drug candidate
Sobi's Tryngolza for severe hypertriglyceridaemia receives EU approval
Oncoinvent reports favourable interim safety results for Radspherin in phase 2 ovarian cancer trial
Rakuten Medical launches Phase 1 first-in-human trial of PD-L1-targeted RM-0256 photoimmunotherapy
BioArctic and Eisai report positive five-year data for Leqembi in early Alzheimer's disease
Akeso submits sNDA for ivonescimab chemotherapy combination in first-line biliary tract cancer